ELEKTA AB/ADR (EKTAY) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) from a sell rating to a hold rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “

Separately, ValuEngine cut shares of ELEKTA AB/ADR from a buy rating to a hold rating in a report on Tuesday, April 9th.

Shares of EKTAY stock opened at $11.39 on Monday. ELEKTA AB/ADR has a 12-month low of $10.95 and a 12-month high of $14.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.93 and a current ratio of 1.18. The company has a market capitalization of $4.05 billion, a P/E ratio of 32.54, a P/E/G ratio of 2.26 and a beta of 0.49.

ELEKTA AB/ADR (OTCMKTS:EKTAY) last issued its earnings results on Friday, February 22nd. The company reported $0.06 earnings per share (EPS) for the quarter. ELEKTA AB/ADR had a net margin of 9.35% and a return on equity of 16.86%. The company had revenue of $367.04 million for the quarter. As a group, equities analysts predict that ELEKTA AB/ADR will post 0.35 EPS for the current year.

ELEKTA AB/ADR Company Profile

Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.

Read More: What is the Fibonacci sequence?

Get a free copy of the Zacks research report on ELEKTA AB/ADR (EKTAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.